Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Histologic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg may leads to higher histologic remission compared with placebo (low certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Remission (combined clinical and endoscopic remission) · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in remission (combined clinical and endoscopic remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · Adult patients with active ulcerative colitis
Budesonide MMX® 6 mg showed no clear difference in clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Interferon‐B‐1a showed no clear difference in improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
IBDQ at week 8 · people with active UC
1 finding from 1 review
QoL · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Vedolizumab probably leads to higher improved IBDQ at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
SF‐36 PCS at week 6 · people with active UC
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
1 finding from 1 review
Health‐related quality of life Multiple different outcome measures used EQ‐5D and EQ‐5D VAS (9 and 26 weeks) (Batterham 2014) SF‐36 PCS and MCS (8 and 26 weeks) (Elliott 2011) · people with active UC
1 finding from 1 review
SF‐36 MCS at week 52 · people with active UC
1 finding from 1 review
IBDQ at weeks 6 or 8 · people with active UC
TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).
2 findings from 1 review
QoL · people with active UC
1 finding from 1 review